International Journal of

Clinical Biostatistics and BiometricsISSN: 2469-5831

Archive

 Open Access DOI:10.23937/2469-5831/1510032

Changes in Mobility during COVID-19 as a Response to Government Imposed Restrictions: A Multiple Regression Analysis for the Top Five Populous U.S States

Eitan Flor, Florence George and BM Golam Kibria

Article Type: Original Article | First Published: November 14, 2020

With the rise of the COVID-19 pandemic, several changes occurred in the lifestyle and habits of human life. These include various voluntary and mandatory governmental restrictions, limiting social interaction by encompassing social distancing, travel limitations, social gatherings, personal mobility, as well as closures and reduced capacities in sectors such as retail, restaurants, and the entertainment industry. The purpose of the restrictions ideally intended to reduce the transmission rate of...

 Open Access DOI:10.23937/2469-5831/1510031

A New Two Parameter Biased Estimator for the Unrestricted Linear Regression Model: Theory, Simulation and Application

Issam Dawoud and BM Golam Kibria

Article Type: Original Article | First Published: November 11, 2020

This paper proposes a new biased estimator for estimating the regression parameters for the multiple linear regression models when the regressors are correlated. Theoretical comparisons and simulations results show that, the proposed estimator performs better than other existing estimators under some conditions in the smaller mean squares error sense. A real-life dataset is analyzed to illustrate the findings of the paper. The ordinary least squares (OLS) estimator is the best linear unbiased es...

 Open Access DOI:10.23937/2469-5831/1510030

Two-stage Adaptive Biomarker-Targeted Clinical Trial Design: Non-Parametric Bayesian and MLE Approaches

Huiding Chen, Ao Yuan and Ming T Tan

Article Type: Research Article | First Published: October 14, 2020

Biomarker targeted two-stage adaptive design is used increasingly in early-stage clinical trials in a variety of therapeutic areas including oncology, where the sample size of the trial is re-estimated based on the first stage data. In such trials often the sample size is moderate, and so incorporating prior information and using robust methods are desirable. In this article, to improve upon existing methods using parametric normal models, we propose a nonparametric Bayesian approach for designi...

 Open Access DOI:10.23937/2469-5831/1510029

Pulmonary Thromboembolism in COVID-19: Proposal for a Scoring System for Diagnosis

Alberto Saraiva Tibúrcio, MD and Fabíola Curvello Leite Tibúrcio, MD

Article Type: Patient Care | First Published: August 26, 2020

Pulmonary thromboembolism is a clinical condition that is difficult to diagnose and highly lethal if not diagnosed and treated in time. The COVID-19 pandemic has greatly increased the incidence of PTE in patients affected by the SARS-CoV-2 virus. On July 16, 2020, at the time of making this manuscript, the COVID-19 pandemic, a disease caused by the new coronavirus SARS-CoV-2, has already reached more than 13.7 million confirmed cases on a global scale and about six thousand deaths daily, totalin...

 Open Access DOI:10.23937/2469-5831/1510028

Bridging Strategies for In Vitro Diagnostic Clinical Trials in a New Region

Robert Magari, PhD, Mohamad Hasan, PhD and Karen Lo

Article Type: Original Article | First Published: July 10, 2020

The need for multiregional clinical trials for in vitro diagnostic devices and extrapolating results in a new region is increasing in recent years. In this paper we are providing strategies for consideration of bridging studies for the two most common types of clinical trials for in vitro diagnostic, method comparison and diagnostic clinical performance trials. Bridging studies should be considered when the expected agreement in the new region is inferior to the agreement in the original trial. ...

Volume 6
Issue 2